What is Akero Therapeutics Debt-to-Equity?
Akero Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.52 Mil. Akero Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $25.78 Mil. Akero Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $535.31 Mil.
Akero Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.05.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Akero Therapeutics's Debt-to-Equity or its related term are showing as below:
AKRO'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.05
Current: 0.05
During the past 7 years, the highest Debt-to-Equity Ratio of Akero Therapeutics was 0.05. The lowest was 0.00. And the median was 0.01.
Akero Therapeutics Debt-to-Equity Historical Data
The historical data trend for Akero Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akero Therapeutics Debt-to-Equity Chart
|
Akero Therapeutics Annual Data
|
|
Trend |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
- |
0.01 |
0.01 |
0.03 |
0.05 |
|
Akero Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.03 |
0.09 |
0.04 |
0.05 |
0.05 |
Competitive Comparison of Akero Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, Akero Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akero Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akero Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Akero Therapeutics's Debt-to-Equity falls into.
Akero Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Akero Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Akero Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akero Therapeutics (Akero Therapeutics) Business Description
Traded in Other Exchanges
Address
601 Gateway Boulevard, Suite 350, South San Francisco, CA, USA, 94080
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
Executives
| Jonathan Young |
officer: Chief Operating Officer |
C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FL, SOUTH SAN FRANCISCO CA 94080 |
| Andrew Cheng |
director, officer: President & CEO |
170 HARBOR WAY, 3RD FLOOR, C/O AKERO THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080 |
| Catriona Yale |
officer: Chief Development Officer |
C/O AKERO THERAPEUTICS INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| William Richard White |
officer: Chief Financial Officer |
C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Timothy Rolph |
officer: Chief Scientific Officer |
C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY, 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| G. Walmsley Graham |
director |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Tomas J. Heyman |
director |
C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Jane Henderson |
director |
C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142 |
| Patrick Lamy |
officer: See Remarks |
AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
| Skorpios Trust |
other: Former 10% owner |
195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030 |
| Montrago Trustees Ltd |
other: Former 10% owner |
195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE, LIMASSOL G4 3030 |
| Blue Horizon Enterprise Ltd |
other: Former 10% owner |
3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110 |
| Ezbon International Ltd |
other: Former 10% owner |
3076, SIR FRANCIS DRAKES HIGHWAY, ROAD TOWN, TORTOLA D8 VG1110 |
| Seth Loring Harrison |
director |
230 PARK AVENUE, SUITE 2800, NEW YORK NY 10169 |
| Chou Judy |
director |
C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BLVD, SUITE 350, SOUTH SAN FRANCISCO CA 64080 |
Akero Therapeutics (Akero Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKRO has been successfully added to your